中国现代医生
中國現代醫生
중국현대의생
CHINA MODERN DOCTOR
2015年
22期
100-102
,共3页
瑞舒伐他汀%原发性高脂血症%胆固醇%低密度脂蛋白
瑞舒伐他汀%原髮性高脂血癥%膽固醇%低密度脂蛋白
서서벌타정%원발성고지혈증%담고순%저밀도지단백
Osuvastatin%Primary hyperlipidemia%Cholesterol%Low-density lipoprotein
目的:评价不同他汀类药物在老年原发性高脂血症中的治疗效果。方法选取2013年1月~2014年11月我院收治的老年原发性高脂血症患者76例,随机分为两组,其中观察组39例,选用瑞舒伐他汀进行治疗,对照组37例,选用阿托伐他汀进行治疗,观察并比较两组患者临床疗效、血脂与炎症因子指标改善程度以及不良反应发生情况。结果观察组临床疗效优良率为92.3%,明显优于对照组的70.3%,差异有统计学意义(P<0.05);在血脂指标改善程度方面,观察组改善幅度大于对照组,差异有统计学意义(P<0.05);观察组炎症因子降低情况优于对照组,差异有统计学意义(P<0.05)。结论瑞舒伐他汀治疗原发性高脂血症的临床疗效好,能有效改善患者血脂指标,降低体内炎症因子浓度,值得在临床上予以推广。
目的:評價不同他汀類藥物在老年原髮性高脂血癥中的治療效果。方法選取2013年1月~2014年11月我院收治的老年原髮性高脂血癥患者76例,隨機分為兩組,其中觀察組39例,選用瑞舒伐他汀進行治療,對照組37例,選用阿託伐他汀進行治療,觀察併比較兩組患者臨床療效、血脂與炎癥因子指標改善程度以及不良反應髮生情況。結果觀察組臨床療效優良率為92.3%,明顯優于對照組的70.3%,差異有統計學意義(P<0.05);在血脂指標改善程度方麵,觀察組改善幅度大于對照組,差異有統計學意義(P<0.05);觀察組炎癥因子降低情況優于對照組,差異有統計學意義(P<0.05)。結論瑞舒伐他汀治療原髮性高脂血癥的臨床療效好,能有效改善患者血脂指標,降低體內炎癥因子濃度,值得在臨床上予以推廣。
목적:평개불동타정류약물재노년원발성고지혈증중적치료효과。방법선취2013년1월~2014년11월아원수치적노년원발성고지혈증환자76례,수궤분위량조,기중관찰조39례,선용서서벌타정진행치료,대조조37례,선용아탁벌타정진행치료,관찰병비교량조환자림상료효、혈지여염증인자지표개선정도이급불량반응발생정황。결과관찰조림상료효우량솔위92.3%,명현우우대조조적70.3%,차이유통계학의의(P<0.05);재혈지지표개선정도방면,관찰조개선폭도대우대조조,차이유통계학의의(P<0.05);관찰조염증인자강저정황우우대조조,차이유통계학의의(P<0.05)。결론서서벌타정치료원발성고지혈증적림상료효호,능유효개선환자혈지지표,강저체내염증인자농도,치득재림상상여이추엄。
Objective To evaluate the different statins in the treatment of elderly patients with primary hyperlipidemia. Methods A total of 76 patients with primary hyperlipidemia admitted in our hospital from January 2013 to November 2014 were randomly divided into two groups. For 39 cases in the observation group, chose rosuvastatin treatment; for 37 cases in the control group, chose the atorvastatin treatment. Two groups of patients were observed and compared in the clinical efficacy, the degree of improvement in various lipid levels and the incidence of adverse reactions. Results The rate of excellent clinical efficacy in the observation group was 92.3%, significantly better than that was the 70.3%in the control group,the difference was statistically significant(P<0.05);The degree of improvement in lipid levels in the observation group was bigger than that in the control group,the difference was statistically significant(P<0.05);inflam-mation factor of the observation group was lower than that in the control group, the difference was statistically signifi-cant(P<0.05). Conclusion The clinical efficacy of rosuvastatin treatment of primary hyperlipidemia is good,can effec-tively improve lipid levels in patients, reduce inflammation in the body concentration factor, deserves in clinical prac-tice.